Featured Research

from universities, journals, and other organizations

KDM1 may represent a new therapeutic target for glioma

Date:
April 7, 2013
Source:
American Association for Cancer Research (AACR)
Summary:
Researchers have generated preclinical data demonstrating that the protein KDM1, which functions as a lysine demethylase, is a potential target for glioma treatment, according to new research.

Researchers have generated preclinical data demonstrating that the protein KDM1, which functions as a lysine demethylase, is a potential target for glioma treatment, according to Gangadhara R. Sareddy, Ph.D., a postdoctoral fellow in the Vadlamudi Laboratory at The University of Texas Health Science Center in San Antonio, who presented the results at the AACR Annual Meeting 2013, held in Washington, D.C., April 6-10.

"We found that KDM1 expression is upregulated in gliomas and have preclinical evidence that suggests pharmaceutical inhibition of the KDM1 axis could have therapeutic implications for the treatment of gliomas," said Sareddy.

Gliomas, the deadliest form of primary central nervous system neoplasms, represent about 70 percent of brain tumors, according to Sareddy. Roughly 20,000 patients are diagnosed with gliomas each year in the United States.

"Patients with malignant gliomas have a survival time of approximately 14 months," Sareddy said. "Novel therapies are urgently needed. Evolving evidence suggests that glioma development is a multistep process that results from changes both in genetic and epigenetic mechanisms. Unlike genetic alterations, epigenetic changes are reversible; therefore, targeting epigenetic changes represents a promising therapeutic approach."

He and his colleagues set out to assess the importance of KDM1 in gliomas. Through immunohistochemical analysis, they found that KDM1 expression was elevated in gliomas. They silenced KDM1 expression with siRNA or inhibited it with pargyline or NCL-1 and found that reducing its expression or inhibiting it pharmacologically reduced glioma cell line growth in vitro. In addition, inhibiting KDM1 pharmacologically reduced the growth of patient-derived primary glioblastoma multiforme cells in vitro and the growth of a human glioma cell line in mice.

Results of mechanistic studies demonstrated that inhibiting KDM1 increased the expression of tumor suppressor p53 target genes through epigenetic modifications, according to Sareddy.

"Because KDM1 plays a critical role in glioma biology and because epigenetic modifications are reversible, pharmacological inhibition of KDM1 could be a potential therapy for gliomas," Sareddy said. "Identification of KDM1 as a therapeutic agent can be readily extended to clinical use with current chemotherapies, providing an additional tool for enhancing survival in patients with glioma."


Story Source:

The above story is based on materials provided by American Association for Cancer Research (AACR). Note: Materials may be edited for content and length.


Cite This Page:

American Association for Cancer Research (AACR). "KDM1 may represent a new therapeutic target for glioma." ScienceDaily. ScienceDaily, 7 April 2013. <www.sciencedaily.com/releases/2013/04/130407132909.htm>.
American Association for Cancer Research (AACR). (2013, April 7). KDM1 may represent a new therapeutic target for glioma. ScienceDaily. Retrieved April 18, 2014 from www.sciencedaily.com/releases/2013/04/130407132909.htm
American Association for Cancer Research (AACR). "KDM1 may represent a new therapeutic target for glioma." ScienceDaily. www.sciencedaily.com/releases/2013/04/130407132909.htm (accessed April 18, 2014).

Share This



More Health & Medicine News

Friday, April 18, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Scientists Create Stem Cells From Adult Skin Cells

Scientists Create Stem Cells From Adult Skin Cells

Newsy (Apr. 17, 2014) The breakthrough could mean a cure for some serious diseases and even the possibility of human cloning, but it's all still a way off. Video provided by Newsy
Powered by NewsLook.com
Obama: 8 Million Healthcare Signups

Obama: 8 Million Healthcare Signups

AP (Apr. 17, 2014) President Barack Obama gave a briefing Thursday announcing 8 million people have signed up under the Affordable Care Act. He blasted continued Republican efforts to repeal the law. (April 17) Video provided by AP
Powered by NewsLook.com
Is Apathy A Sign Of A Shrinking Brain?

Is Apathy A Sign Of A Shrinking Brain?

Newsy (Apr. 17, 2014) A recent study links apathetic feelings to a smaller brain. Researchers say the results indicate a need for apathy screening for at-risk seniors. Video provided by Newsy
Powered by NewsLook.com
Could Even Casual Marijuana Use Alter Your Brain?

Could Even Casual Marijuana Use Alter Your Brain?

Newsy (Apr. 16, 2014) A new study conducted by researchers at Northwestern and Harvard suggests even casual marijuana use can alter your brain. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins